Systems and methods for simple automated protein digestion using magnetic beads
The use of high-responsive magnetic beads for protein digestion through electromagnetic mixing technology solves the problems of low reproducibility and high artifacts in traditional methods, and achieves efficient and automated proteome analysis.
Patent Information
- Application Number
- CN202280080726.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-10-19
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-08
AI Technical Summary
Traditional protein digestion methods have low reproducibility, high artifacts and difficulty in automating, resulting in limited efficiency and accuracy of proteome analysis.
Using electromagnetically mixed magnetic beads to assist protein pretreatment and digestion methods, high-responsive magnetic beads driven through liquid at high speed for mixing, simplifying workflow and making them suitable for automation, avoiding bottle plate movement and centrifugation steps in traditional methods .
Improves reproducibility and throughput of proteome analyses, reduces artifacts, simplifies workflows, makes it easy to automate, and completes the protein digestion process in a short time.
Smart Images

Figure CN118922718A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application was filed as a PCT international patent application on October 19, 2022, and claims the benefit and priority of U.S. Provisional Application Serial No. 63 / 257,417 filed on October 19, 2021, which is incorporated herein by reference in its entirety.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically in XML format and is incorporated herein by reference in its entirety. The XML file was created on October 18, 2022, named Sequence-Listing-18777-0004WOU1.xml and is 4,533 bytes in size. Background Art
[0005] Protein digestion is a labor-intensive sample preparation process for proteomic analysis. Protein digestion can be used to aid in the identity confirmation of protein therapeutics and / or to monitor degradation events such as oxidation or deamidation. Peptide mapping can be used for sequence verification of purified proteins with known amino acid sequences. Peptide mapping analysis includes enzymatic protein digestion, peptide separation, and peptide detection. Protein digestion can include reduction and alkylation of cysteine thiols, and enzymatic cleavage of proteins into peptides followed by LC-MS / MS analysis. Traditional protein digestion methods can result in low reproducibility, high artifacts, and incompatibility with automation.
[0006] Enzymatic digestion may cause artifactual modifications of peptides due to exposure to various buffers, reducing and alkylating agents, and elevated temperatures. Protein modifications such as asparagine deamidation, N-terminal glutamine cyclization, and methionine oxidation may be promoted by elevated temperatures or high pH, and the modifications may be exacerbated over time. The amount of these artifacts or modifications is proportional to the incubation time of the protein sample in the reducing / alkylating buffer and in the digestion buffer (where the peptides are fully exposed to the solvent).
[0007] There is a need for simple and automatable protein digestion methods / systems that improve reproducibility, throughput and reduce artifacts in proteomic analysis. Summary of the invention
[0008] The present disclosure provides improved methods, systems and kits for protein digestion, including magnetic bead-assisted protein pretreatment using electromagnetic mixing, and protein digestion using magnetic beads that respond to a changing magnetic field. The entire workflow can be performed on a single device without moving vials / plates from beginning to end. The entire workflow is simple and easy to automate. In contrast, the traditional workflow involves the movement of vials / plates, centrifugation and additional consumables, which is very complex and difficult to automate.
[0009] A simple and automatable workflow is provided, enabled by a novel magnetic mixing technology, whereby liquids can be efficiently mixed by highly responsive magnetic beads that are driven through the liquid at high speed by a changing magnetic field. This mixing technology can be used to perform protein pretreatment and digestion in one location, thus simplifying the workflow and being compatible with automation. In a preferred embodiment, the denaturant is compatible with mass spectrometry to avoid desalting by centrifugation.
[0010] The present disclosure provides a method for preparing a protein analyte for characterization, comprising pre-treating the protein analyte in a changing magnetic field in the presence of a first magnetic bead to provide a pre-treated protein analyte; and enzymatically digesting the pre-treated protein analyte to provide a plurality of peptides. Characterization may include analyzing the plurality of peptides, including LC-MS / MS.
[0011] Pretreatment may include mixing a protein analyte and a chaotropic agent in an aqueous buffer with first magnetic beads in a varying magnetic field to provide a denatured protein solution. Pretreatment may include adding a reducing agent to the denatured protein solution to provide a reduced denatured protein analyte. Pretreatment may include exposing the denatured protein analyte to an alkylating agent to provide an alkylated protein analyte. Pretreatment may include quenching excess alkylating agent by adding a reducing agent to the alkylated protein analyte to provide a pretreated protein analyte.
[0012] Digestion may include mixing the pre-treated protein analyte with an endopeptidase in the presence of first magnetic beads in a varying magnetic field to provide a plurality of peptides.
[0013] Endopeptidase can be selected from the group consisting of trypsin, chymotrypsin, LysC, LysN, AspN, GluC and ArgC. Endopeptidase can be free endopeptidase or immobilized endopeptidase. Immobilized endopeptidase can be immobilized on the surface of the second magnetic bead.
[0014] The first magnetic bead and / or the second magnetic bead can independently comprise ferrimagnetic particles, superparamagnetic particles, ferromagnetic particles, paramagnetic particles or mixtures thereof. The first magnetic bead and / or the second magnetic bead can independently have a high magnetic response, with a Bmax in the range of about 20emu / g to about 250emu / g, 40emu / g to 200emu / g, 50emu / g to 150emu / g or 80emu / g to 100emu / g. The first magnetic bead and / or the second magnetic bead can independently have a Bmax of >5m 2 / g, >7m 2 / g, or >10m 2 / g high surface area.
[0015] The first magnetic bead and / or the second magnetic bead independently may further comprise a coating, optionally wherein the coating is selected from the group consisting of a silica shield, a silane linker, and a polymer coating.
[0016] The first magnetic bead and / or the second magnetic bead may independently comprise a functional group coated surface, optionally wherein the functional group coated surface is selected from the group consisting of carboxyl, amino, hydroxyl, thiol, tosyl, epoxy, alkyl, vinyl and aryl groups.
[0017] The first magnetic bead and / or the second magnetic bead may independently comprise a bioaffinity adsorbent, optionally selected from the group consisting of streptavidin, avidin, neutravidin, captavidin and biotin.
[0018] In some embodiments, the first magnetic beads do not comprise an immobilized endopeptidase.
[0019] The varying magnetic field may be generated in an electromagnetic mixer. The electromagnetic mixer may include a plurality of electromagnets capable of generating an AC driven oscillating magnetic field.
[0020] The protein analyte may be selected from the group consisting of monoclonal antibodies, isolated immunoglobulins, recombinant proteins, isolated proteins, and complex protein samples; optionally, wherein the complex protein sample is selected from the group consisting of tissue samples, blood samples, serum samples, and plasma samples.
[0021] The chaotropic agent can be an organic chaotropic agent. The organic chaotropic agent can be selected from the group consisting of trifluoroethanol (TFE), ethanol, 2-propanol, n-butanol and phenol. The chaotropic agent can be an immobilized chaotropic agent; optionally, wherein the chaotropic agent is immobilized on the first magnetic bead or the third magnetic bead.
[0022] The reducing agent may be selected from the group consisting of dithiothreitol (DTT), dithioerythritol (DTE), tris(2-carboxyethyl)phosphine hydrochloride (TCEP), β-mercaptoethanol (βME) and L-glutathione (GSH).
[0023] The alkylating agent may be selected from the group consisting of 2-iodoacetamide (IAM), iodoacetic acid (IAC) and chloroacetamide (CAA).
[0024] Pretreatment can be completed in a time period ranging from 5 minutes to 90 minutes, or 10 minutes to 60 minutes. Enzyme digestion can be completed in a time period ranging from 5 minutes to 60 minutes, or 10 minutes to 60 minutes. In some embodiments, pretreatment and enzyme digestion can be performed sequentially or simultaneously.
[0025] A kit for preparing a protein analyte for characterization is provided, comprising a first container including a first magnetic bead; a chaotropic agent; a reducing agent; an alkylating agent; and an endopeptidase. The first magnetic bead may include a surface coated with a functional group, optionally wherein the surface coated with the functional group is selected from the group consisting of carboxyl, amino, hydroxyl, thiol, tosyl, epoxy, alkyl, vinyl and aryl groups; optionally wherein the first magnetic bead does not include an immobilized endopeptidase. The endopeptidase may be selected from the group consisting of trypsin, chymotrypsin, LysC, LysN, AspN, GluC and ArgC. The endopeptidase may be a free endopeptidase or an immobilized endopeptidase. The immobilized endopeptidase may be immobilized on a second magnetic bead. The chaotropic agent may be a free chaotropic agent or an immobilized chaotropic agent. The immobilized chaotropic agent may be immobilized on the first magnetic bead or on a third magnetic bead.
[0026] A system is provided that includes a kit according to the present disclosure and an electromagnetic mixer that includes a plurality of electromagnets capable of generating an AC driven oscillating magnetic field. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 Transmission electron microscopy (TEM) images of eMagBeads according to the present disclosure are shown. The exemplary beads are protected by 10 nm silica.
[0028] Figure 2 Comparison of workflow schemes for trypsin digestion of protein analytes is shown. The prior art "in solution" workflow (above) requires several manual operations, including moving vials between steps, requiring a desalting step, requiring a filtration step, and requiring a centrifugation step. The prior art in solution workflow is also difficult to automate and requires more than 2 hours to complete the workflow. Compared to the prior art in solution workflow, the eMag trypsin digestion workflow of the present invention (below) reduces the number of manual steps because there is no need to move vials between steps, no desalting, no filtration, and no centrifugation. The trypsin digestion method of the present invention is easily automated and requires less than 2 hours to complete the workflow.
[0029] Figure 3The ultraviolet (UV) spectra (upper panel) and high-resolution mass spectrometry (MS) (lower panel) results of three different trypsin digests of Herceptin are shown, including solution digestion of the prior art, eMag-immobilized trypsin of the present invention, and eMag-free trypsin of the present invention. Figure 3 (Bottom) shows the LC-MS data in Table 1, including the number of unique peptides, the number of missed cleavages (#), % trypsin artifacts, VSNK (SEQ ID NO: 3) deamidation area %, VVSVLTVLHQDWLNGK (SEQ ID NO: 1) deamidation area %, peptide GFYPSDIAVEWESNGQPENNYK (SEQ ID NO: 2) deamidation area %, DTLMISR (SEQ ID NO: 4) oxidation area %, automatically verified sequence coverage (%), and total area of verified peptides. As shown in the LC-MS data, the two eMag workflows of the present invention at least produce similar trypsin digestion results compared to the prior art "in solution" workflow. DETAILED DESCRIPTION OF THE INVENTION
[0031] The present disclosure provides improved and simplified methods and kits for endopeptidase digestion of protein analytes, for example for characterization by LC-MS / MS analysis. The methods can be implemented without the need for moving vials, filtering, centrifuging or desalting, and are suitable for automation.
[0032] Prior art "in solution" trypsin digestion workflows for protein analytes typically include denaturation and reduction by vortex mixing (30 min), alkylation (15 min), quenching (1 min), desalting by centrifugation (60 min), and vortex digestion with free trypsin at 37°C (30 min) prior to LC-MS / MS characterization of the tryptic digest, e.g. Figure 2 (above). See, e.g., Da Ren et al., 2009, An improved trypsindigestion method minimizes digestion-induced modifications on proteins, Anal Biochem 392(1): 12-21. The prior art "in solution" workflow requires several manual operations, including moving vials between steps, requiring a desalting step, requiring a filtration step, and requiring a centrifugation step. Therefore, in-solution trypsin digestion is also difficult to automate and requires more than 2 hours to complete the workflow.
[0033] Provided herein are improved methods and kits for trypsin digestion workflows of protein analytes. A representative eMag trypsin digestion workflow of the present invention is as follows Figure 2 As shown in the figure below: denaturation and reduction are performed by effective mixing with electromagnetic beads in a changing magnetic field (carboxylated eMB), alkylation (30 minutes), quenching (1 minute), dilution (1 minute), and digestion (30 minutes) using trypsin-immobilized eMB (Ty-eMB) or free trypsin in a changing magnetic field. Compared with the prior art in solution workflows, the eMag trypsin digestion workflow of the present invention (figure below) reduces the number of manual steps, does not require moving vials between steps, does not require desalting, does not require filtration, does not require centrifugation, is easily automated, and requires less than 2 hours to complete the workflow.
[0034] definition
[0035] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the disclosure.
[0036] The singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.
[0037] The term "and / or" or "and or" indicates and encompasses any and all possible combinations of one or more of the associated listed items.
[0038] The term "about" when referring to a measurable value such as amount of compound, dosage, time, temperature, etc., is intended to encompass variations of 10%, 5%, 1%, 0.5%, even 0.1% of the specified amount.
[0039] The terms "include" and / or "comprising" when used in this specification specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof. Unless otherwise defined, all terms, including technical and scientific terms used in the description, have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. In the event of a conflict in terms, the present specification shall prevail.
[0040] All patents, patent applications, and publications mentioned herein are incorporated by reference in their entirety.
[0041] The embodiments described in one aspect of the present disclosure are not limited to the described aspects. These embodiments can also be applied to different aspects of the present disclosure as long as these embodiments do not prevent these aspects of the present disclosure from achieving their intended purposes.
[0042] The term "ferrimagnetic particles" refers to particles comprising ferrimagnetic materials. Ferrimagnetic particles can respond to an external magnetic field (e.g., a changing magnetic field), but can demagnetize when the external magnetic field is removed. Thus, ferrimagnetic particles can be effectively mixed through a sample by an external magnetic field, and effectively separated from a sample using a magnet or electromagnet, but can remain suspended without magnetically induced aggregation.
[0043] The term "remanence" refers to the remaining magnetism that a material retains after removing a magnetic field. A material with a high remanence retains a large magnetic field intensity after removing a magnetic field, while a material with a low remanence has a small or zero magnetic field intensity after removing a magnetic field. The remanence of a magnetic material can be in the range of from about 0emu / g to about 30emu / g, about 0emu / g to about 20emu / g, about 1emu / g to about 10emu / g, about 3emu / g to about 5emu / g, or less than, equal to or greater than about 0emu / g, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or about 30emu / g.
[0044] As used herein, the term "functional group coated surface" refers to a surface coated with moieties each having free functional groups that bind to magnetic particles; as a result, the surface of the magnetic particles is coated with moieties containing functional groups. The functional group can be used as a bioaffinity absorbent for covalently attaching biomolecules in solution. In one example, the functional group is a carboxylic acid. A suitable moiety with a free carboxylic acid functional group is a succinic acid moiety, in which one carboxylic acid group is bound to the amine of the aminosilane via an amide bond, and the second carboxylic acid is a free carboxylic acid group attached or bound to the surface of the magnetic particle. The surface coated with the functional group can be selected from carboxyl, amino, hydroxyl, thiol, tosyl, epoxy, alkyl, vinyl or aryl groups.
[0045] The functional groups can be used to covalently attach "bioaffinity adsorbents" such as streptavidin, avidin, neutravidin, captavidin, biotin, etc.
[0046] According to further examples, the surface can be covalently bound to an enzyme, a protein, a deoxyribonucleic acid (DNA), a ribonucleic acid (RNA), or an immunoglobulin. The enzyme can be an endopeptidase. The enzyme can be trypsin.
[0047] The term "peptide sequence coverage" (SQ%) can be used as a measure of the completeness of protein digestion and the detection efficiency of various tryptic peptides, and is a common way to define digestion rates in proteomics (Hustoft et al. (2012). A Critical Review of Trypsin Digestion for LC-MS Based Proteomics, Integrative Proteomics, Hon-Chiu Leung (Ed.), ISBN: 978-953-51-0070-6, InTech, Available from: www.intechopen.com / books / integrative-proteomics / a-critical-review-of-trypsin-digestion-for-lc-ms-basedproteomics).
[0048] The term "alkylation efficiency" is defined as the quantitative relationship between the number of cysteine residues detected during the reaction that have been modified by the alkylating agent and the total number of cysteine residues detected in the sample, as determined by analyzing the sample using mass spectrometry, optionally followed by a database search. A non-limiting example includes alkylation of cysteine with an alkylating agent such as chloroacetamide (CAA) or iodoacetic acid (IAC), which increases the mass of the peptide by 57.021 or 58.005 Daltons, respectively. The increase in mass is measured using a mass spectrometer and quantified during the database search.
[0049] Magnetic particles
[0050] Any suitable magnetic particles may be used, as long as they can be mixed throughout the container. Magnetic particles suitable for mixing in response to a changing magnetic field are described in WO 2020 / 018919 to Beckman Coulter, Inc.
[0051] Sample processing methods and systems are provided for mixing, separating, filtering or otherwise processing samples (e.g., fluid samples) by utilizing magnetic particles that move under the influence of a magnetic assembly disposed at the periphery of a container containing the sample. The magnetic beads may include ferrimagnetic particles, superparamagnetic particles, ferromagnetic particles, paramagnetic particles, or mixtures thereof.
[0052] The magnetic particles can be ferrimagnetic particles. The ferrimagnetic particles can be effectively manipulated (e.g., moved) by a changing magnetic field generated by a magnetic assembly. The ferrimagnetic particles can have a high response to a magnetic field so that when there is an external changing magnetic field, the ferrimagnetic particles are easily mixed into a sample. The ferrimagnetic particles can also have a low remanence so that when the external changing magnetic field is removed, the ferrimagnetic particles are not magnetically attracted to each other. As a result, the ferrimagnetic particles can remain suspended without magnetically induced aggregation after mixing, and therefore will not inhibit binding or elution.
[0053] In addition, the magnetic particles should be suspended in the sample for a suitable time after mixing. Those skilled in the art will recognize that many characteristics of the magnetic particles will affect this characteristic. For example, the density of the magnetic particles and remanence (for example, residual magnetism) can affect the length of time that the magnetic particles are suspended in the sample after removing the magnetic field of the change. In some examples, it is desirable to separate the magnetic particles from the sample. In these examples, a collection assembly (such as a magnet or an electromagnet) can be used to separate the magnetic particles from the container magnetic separation, as described herein.
[0054] The magnetic particles used in the present disclosure have enough response to the magnetic field so that they can effectively move through the sample. In general, the range of field strength can be the same as any electromagnet, as long as it can move the particles. For example, the magnetic field has an intensity between about 10mT to about 100mT, between about 20mT to about 80mT, and between about 30mT to about 50mT. In some examples, more powerful electromagnets can be used to mix the less responsive particles. In some examples, the magnetic field can be concentrated in the sample as much as possible. In addition, the electromagnet can be as close to the sample as possible because the magnetic field strength decreases with the square of the distance.
[0055] Ferromagnetic particles may include ferrites. Ferrites include ceramic materials that include combinations of iron oxides and inorganic compounds of metal, non-metal or metalloid atoms. For example, ferrites may include iron (III) oxide (Fe2O3) mixed with one or more additional metal elements such as barium, manganese, nickel, zinc, titanium or any other suitable metal element. Other examples of ferrites include Fe2TiO2, FeTiO2, MnFeO4, NiFe2O4, MgFe2O4. Other examples of ferrites include iron cores containing sulfides or oxyhydroxides, such as FCTSS, Fe3S4, FeS or FeOOH.
[0056] Magnetite (Fe3O4) is an example of a magnetic material that can be used in embodiments described herein, which is an example of a ferrite. Magnetite contains Fe 2+ and Fe 3+ ions. In some cases, Fe 2+ and Fe 3+The electron spins of the ions can be coupled in the crystal structure so that magnetite is ferrimagnetic, as described herein. However, in some examples, the ferrimagnetic particles include any ferrimagnetic material (e.g., ferrite). According to some examples, the ferrimagnetic material (e.g., ferrite) may not be magnetite (Fe3O4), however, in some examples, magnetite is a suitable ferrimagnetic material.
[0057] Ferrites can be divided into two main families (hard ferrites and soft ferrites) based on their magnetic coercivity (eg, the ability of a material to withstand an external magnetic field without demagnetization).
[0058] Hard ferrites have high magnetic coercivity and high remanence after magnetization. Hard ferrites can be used to make permanent magnets because they are not easily demagnetized without an external magnetic field because they can have high remanence. Examples of hard ferrites include strontium ferrite and barium ferrite.
[0059] Soft ferrites have low magnetic coercivity. Soft ferrites also have low remanence after magnetization. The magnetization of soft ferrites can be changed more easily than that of hard ferrites. In addition, the direction of magnetization of soft ferrites can be easily reversed without dissipating a lot of energy (e.g., via hysteresis losses). Soft ferrites can also have high resistivity, which prevents the formation of eddy currents in the material, which is another source of energy loss.
[0060] Soft ferrites may include manganese zinc (MnZn) ferrites and nickel zinc (NiZn) ferrites. Thus, in some examples, the ferrimagnetic particles include MnZn ferrites. In other examples, the ferrimagnetic particles include NiZn ferrites. Ferrimagnetic particles comprising MnZn ferrites and / or NiZn ferrites may be magnetized in the presence of an external magnetic field and are therefore able to move in the presence of an external magnetic field, but due to their low remanence, they will not aggregate due to magnetic aggregation after the external magnetic field is removed.
[0061] Some ferrites can be considered semi-hard ferrites. The properties of semi-hard ferrites are between those of soft ferrites and those of hard ferrites. For example, cobalt ferrite (CoFe2O4) is a semi-hard ferrite that can be magnetized in the presence of an external magnetic field (such as a changing magnetic field generated by a magnetic component), but does not have a high remanence after the external magnetic field is removed, so that the ferrimagnetic particles comprising the cobalt ferrite core do not aggregate due to magnetically induced aggregation.
[0062] The magnetic particles can be of various shapes, which can be regular or irregular. In some examples, the shape maximizes the surface area of the particles. For example, the magnetic particles can be spherical, rod-shaped, elliptical, or any other suitable shape. The magnetic particles can have various densities, which can be determined by the composition of the core. In some examples, the density of the magnetic particles can be adjusted by a coating, as described herein.
[0063] The strength of the magnetic field can be determined in Gauss. Gauss is the unit of magnetic flux density B in the Gauss system, equal to Mx / cm 2 or g / Bi / s 2 Gauss is the unit used to measure magnetic field strength, and a Gaussmeter device can be used to make this measurement. The higher the Gauss number, the greater the force of the magnetic field, and therefore the greater the distance from surrounding magnets.
[0064] Magnetic particles can include magnetic materials with a maximum magnetic field strength (Bmax) of about 20emu / g to about 250emu / g, 40emu / g to 200emu / g, 50emu / g to 150emu / g or 80emu / g to 100emu / g. Bmax can be >40, >50, >60 or >70emu / g. Bmax can be measured by SQUID (superconducting quantum interference device). Magnetic particles or magnetic beads can have ultrahigh magnetic response, for example, with a Bmax in the range of about 80-100emu / g or about 89emu / g. This is superior to many commercially available magnetic beads with <40emu / g.
[0065] In some embodiments, the magnetic particles may include a magnetic material having a maximum magnetic field strength (Bmax) in the range of about 20 emu / g to about 250 emu / g and a remanence in the range of about 0 emu / g to about 30 emu / g.
[0066] The magnetic particles can range from about 1 nm average diameter to 1 mm average diameter. In some examples, the magnetic particles can have an average diameter in the range of 50 nm to 500 nm. In some examples, the magnetic particles can have an average diameter in the range of 100 to 200 nm. The magnetic beads can have a diameter in the range of about 80 to about 120 nm or about 100 nm. The average diameter can be measured by microscopy, such as by TEM imaging, such as Figure 1 shown.
[0067] The magnetic particles can be substantially solid or can have a certain degree of porosity. When the magnetic particles do include a certain degree of porosity, the pore size of each hole can be in the range of about 5A to about 1000A, about 50A to about 500A. At least a plurality of holes can be through holes (e.g., extending completely between relative surfaces). The pore size or total porosity of the magnetic particles can be determined according to a variety of suitable methods. For example, the main volume of the ideal (e.g., non-porous) magnetic particles can be determined first, and then the volume of the actual porous skeleton material can be determined. The porosity is then calculated by subtracting the volume of the actual porous skeleton material from the ideal magnetic particle volume. The porosity or individual pore size of the magnetic particles can also be determined by using the optical measurement of a microscope and processing images to measure individual holes.
[0068] The magnetic particles have sufficient surface area to allow effective binding of the endopeptidase. In some examples, the surface area of the magnetic particles can be from about 0.1 m 2 / g to about 500m 2 / g, about 1m 2 / g to about 200m 2 / g, or about 10m 2 / g to about 100m 2 In some embodiments, the magnetic particles or beads have a size of >5 m 2 / g, >7m 2 / g or >10m 2 / g surface area. Surface area can be measured by BET surface analysis. Brunauer-Emmett-Teller (BET) surface area analysis provides an assessment of the specific surface area of a material, measured as a function of relative pressure using a fully automated analyzer by nitrogen multilayer adsorption. This technique covers external area and pore area assessment to determine the total specific surface area (m 2 / g).
[0069] The magnetic particles described herein may comprise several different materials. Where a mixture of materials is present, the total magnetic content of the magnetic particles may constitute at least 50 wt % of the magnetic particles, at least 70 wt % of the magnetic particles, at least 80 wt % of the magnetic particles, at least 90 wt % of the magnetic particles or even 100 wt % of the magnetic particles.
[0070] The magnetic particles can include any magnetic particles described herein. For example, the non-magnetic material constituting the balance of the magnetic particles can include any coating material described herein. The non-magnetic materials can be used as coatings to encapsulate the magnetic portion of the magnetic particles, and they can also be used as functional components to interact and bind with the analyte of interest. The non-magnetic materials can also be used as filler components.
[0071] Magnetic particles or beads can be surface functionalized with carboxyl, amino, hydroxyl, silica, streptavidin or endopeptidase moieties. Magnetite particles or beads can have a magnetite core. Magnetite particles or beads can have a magnetite core coated with a silica shielding layer. The silica shielding layer can be attached to a silane linker. The silane linker can be attached to a polymer. The polymer can be surface functionalized with carboxyl, amino, hydroxyl, silica, streptavidin surface functional groups. In a specific embodiment, the magnetic beads or magnetic particles have carboxyl surface functional groups. The magnetic beads or magnetic particles can be covalently bound to an endopeptidase. The magnetic beads or magnetic particles can be covalently bound to trypsin.
[0072] The magnetic particles can be coated and / or functionalized by any method known in the art. The coating can be, for example, a polymer layer or a silicon dioxide layer. Exemplary polymer layers can include polyethylene, polystyrene, polymethyl methacrylate, polyvinyl alcohol, or any other suitable polymer.
[0073] Single or multiple layer coatings may be employed. For example, magnetic particles may be coated with a silica layer, a polymer coating and / or functional groups.
[0074] For example, the synthesis of core-shell Fe3O4 nanoparticles (NPs) can be carried out by hydrolyzing tetraethyl orthosilicate (TEOS) in the presence of Fe3O4 nanoparticles to provide silica-coated magnetite core-shell particles. For example, Fe3O4 nanoparticles (NPs) can be dispersed in water using an ultrasonic water bath and then mixed with an aqueous ammonia solution (25 wt%) and ethanol. TEOS can be added dropwise to the Fe3O4 suspension and stirred overnight at room temperature. The product can be separated using an external magnet, washed with water and dried at 50°C. The particles can be characterized by X-ray diffraction (XRD), transmission electron microscopy (TEM), high-resolution TEM, selected area electron diffraction (SAED) and UV-Vis absorption spectroscopy (UV-Vis). Hui et al., 2011, Nanoscale, 3(2):701-5. See also WO2020018919, which is incorporated herein by reference in its entirety.
[0075] Silica-coated magnetite core-shell particles can be treated with 3-aminopropyltriethoxysilane (Silane KH-550) to provide amino-functionalized silica-coated magnetic beads. Amino-functionalized silica-coated magnetic beads can be treated with ClCH2CO2Na to provide carboxyl-functionalized magnetic beads.
[0076] The polymer-coated magnetic core can be prepared by, for example, dispersing about 4 g of 100 nm magnetite cores in 100 ml of water under stirring. 10 mL of acrylic acid is added to a flask with K2S208 under stirring to obtain a uniform suspension. The suspension is heated to 80°C and stirred for 15 hours. The suspension is cooled to room temperature and a permanent magnet is used to collect the solid from the suspension. The collected solid is washed with water and dried at 60°C to provide poly(acrylic acid)-coated magnetic beads.
[0077] An example of a class of magnetic beads (eMBs) developed in the present disclosure comprises a magnetite core that is shielded by silica, surrounded by a silane linker and a polymer from the inside-out direction. The polymer can be covalently attached to surface functional groups, such as carboxyl, amino, hydroxyl, or silica groups. For example, the surface functional groups can be used to covalently attach bioaffinity adsorbents (e.g., streptavidin) or endopeptidases (e.g., trypsin). The eMBs can exhibit high magnetic response, for example, with a Bmax of about 89emu / g compared to <40emu / g for commercial magnetic beads. The eMBs can exhibit >10m 2 / g high surface area.
[0078] Trypsin (eg, bovine trypsin, recombinant porcine trypsin, TPCK-treated trypsin) or a chaotropic agent can be immobilized to the surface of the magnetic particles using surface functional groups by any suitable method known in the art.
[0079] In one example, trypsin-immobilized magnetic beads can be produced by mixing 0.5g of poly(acrylic acid)-coated magnetic beads according to the present disclosure with 20mL of 0.1M sodium phosphate buffer (pH 7.5) and 50mg of TPCK-treated trypsin in a flask. The mixture is stirred to prepare a uniform suspension. 200mg of 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate is added to the suspension. The suspension is kept at 4°C for 24 hours under stirring. The product is collected using a permanent magnet and washed with water 5 times. The product is then redispersed in a 50mM aqueous acetic acid solution and stored at 4°C.
[0080] In another example, trypsin-immobilized magnetic beads can be produced by: treating the carboxylated magnetic beads according to the present disclosure with EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) activation chemistry to produce active ester intermediates, and then exposing to endopeptidase (e.g., trypsin), wherein primary amines such as lysine side chains can be covalently attached via active esters to form covalently attached immobilized endopeptidase. Specifically, 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) chemistry can be used to activate carboxylated eMagbead. The beads can be incubated at room temperature for 1 hour with a solution of 26 mg of EDC (Sigma, St.Louis, MO) per gram of beads dissolved in 0.1M 2-(N-morpholino) ethanesulfonic acid (MES) buffer at pH 4.5. Activation can be terminated by rinsing several times with MES buffer and deionized water. To complete immobilization, the activated beads can be incubated with 40 μg of endopeptidase per gram of beads in a 0.1M sodium phosphate buffer at pH=7.0. This process can be completed by blocking the remaining active sites using phosphate buffered saline (PBS) and 0.1% v / v Tween 20 solution. After enzyme immobilization, the beads can be washed several times with water or 1.0M NaCl. The enzyme-immobilized beads can be stored in a deionized water solution at 4-8°C.
[0081] In some examples, the magnetic beads of trypsin coating or surface functionalized magnetic beads can be purchased commercially. For example, magnetic particles with immobilized trypsin and streptavidin can be purchased from Perfinity (West Lafayette, India). The beads of silanol coating can be obtained from Chemicell (Berlin, Germany), and the superparamagnetic beads of carboxyl functionalization can be obtained from Interchim (Montlucon, France).
[0082] Reagents
[0083] Chaotropic agents can be used to denature or partially denature protein analytes in solution (denaturants). A "chaotropic agent" is a compound that is capable of disrupting the hydrogen bond network in an aqueous solution between water molecules and a protein analyte in solution, and can be used to denature or partially denature a protein analyte. Chaotropic agents increase the entropy of a system by interfering with intermolecular interactions mediated by non-covalent forces such as hydrogen bonds, van der Waals forces, and the hydrophobic effect. Any suitable chaotropic agent can be used as a denaturant. A chaotropic agent can be an organic alcohol or a chaotropic salt. An organic alcohol can be a C 2-6 Organic alcohol, of which C 2-6Can be straight chain or branched alkyl or aryl, optionally containing one or more halogen substituents. Optional halogen substituents can be F, Cl, Br, I. Optional halogen substituents can be F or Cl. Examples of organic alcohol chaotropic agents include trifluoroethanol (TFE), ethanol, 2-propanol, n-butanol and phenol. Examples of other chaotropic agents can include urea or thiourea. Examples of chaotropic salts can include guanidine hydrochloride (GdnHCl), guanidine thiocyanate, magnesium chloride, sodium chloride, sodium bromide, lithium perchlorate, lithium acetate, sodium acetate, potassium acetate, NaClO4, NaNO3, CF3COONa, CCl3COONa and NaSCN. Chaotropic agents can be purchased from, for example, Sigma-Aldrich. Preferably, the chaotropic agent is compatible with mass spectrometry (MS) and therefore does not require desalting. MS compatible chaotropic agents can be used to avoid the desalting step in the process. MS compatible compatible chaotropic agents can be TFE. In some embodiments, the chaotropic agent is C 2-6 Organic alcohol, of which C 2-6 It can be a straight chain or branched alkyl or aryl group, optionally containing one or more halogen substituents. The chaotropic agent can be TFE. In some embodiments, the chaotropic agent is not guanidine hydrochloride (Gdn HCl), guanidine thiocyanate, urea or thiourea. In some embodiments, the chaotropic agent is not a guanidine salt. In some embodiments, the chaotropic agent is not urea or thiourea. In some embodiments, the chaotropic agent is not a chaotropic salt. In some embodiments, the chaotropic agent can be immobilized on an eMag Bead according to the present disclosure. The denaturation step can be carried out at a temperature ranging from about 4°C to about 60°C, about 15°C to about 55°C, about 20°C to about 30°C, or about 23°C. The denaturation step can be carried out within a period of time ranging from about 2 minutes to about 60 minutes, about 5 minutes to about 50 minutes, or about 15 minutes to about 30 minutes. The denaturation step can be carried out sequentially, overlappingly or simultaneously with the reduction step.
[0084] "Reducing agent" is used to reduce the disulfide bonds in the protein analyte (i.e., cystine) to cysteine thiol moieties. The reducing agent can be any suitable reducing agent. The reducing agent can be dithiothreitol (DTT), dithioerythritol (DTE), tris (2-carboxyethyl) phosphine hydrochloride (TCEP), β-mercaptoethanol (βME) or L-glutathione (GSH). The reducing agent can be DTT. The reduction step can be carried out at a temperature ranging from 4 ° C to about 60 ° C, 15 ° C to about 55 ° C, about 40 ° C to about 50 ° C or about 45 ° C. The reduction step can be carried out within a period of time ranging from about 2 minutes to about 60 minutes, about 5 minutes to about 50 minutes, or about 15 minutes to about 30 minutes.
[0085] "Alkylating agents" are used to alkylate free cysteine thiols in reduced protein analytes. Alkylating agents react with cysteine residues in proteins. It is used to modify -SH groups to prevent disulfide bonds from being reformed after cystine residues are reduced to cysteine residues. The alkylating agent can be any suitable alkylating agent. The alkylating agent can be 2-iodoacetamide (IAM), iodoacetic acid (IAC), chloroacetamide (CAA). Alkylating agents can be commercially available from, for example, Sigma-Aldrich or ThermoFisher. In some embodiments, the alkylating agent is IAM. Cysteine is reduced and then alkylated with IAM, resulting in the covalent addition of carbamidomethyl groups and preventing the formation of disulfide bonds. Alkylation of cysteine residues with 2-iodoacetamide (IAM), chloroacetamide (CAA) or iodoacetic acid (IAC) increases the mass of the peptide by, for example, 57.046, 57.021 or 58.005 Daltons, respectively. A mass spectrometer can be used to measure the increase in mass. The alkylation step may be performed at a temperature ranging from about 4° C. to about 60° C., about 15° C. to about 55° C., about 20° C. to about 30° C., or about 23° C. The alkylation step may be performed for a period of time ranging from about 2 minutes to about 60 minutes, about 5 minutes to about 50 minutes, or about 15 minutes to about 35 minutes, or about 20 minutes to about 30 minutes.
[0086] "Endopeptidase" is an enzyme that can cause proteolytic cleavage within a polypeptide chain rather than at the terminal amino acid at either end of the polypeptide. For example, the endopeptidase can be trypsin, chymotrypsin, LysC, LysN, AspN, GluC, ArgC. In some specific examples, the endopeptidase can be trypsin. Suitable endopeptidase can be commercially available, for example, from Sigma-Aldrich (Saint Louis, MO; Millipore Sigma, Burlington, MA, a subsidiary of Merck KGaA), Promega Corporation, Madison, WI or Pierce Biotechnology, Rockford, IL / Thermo Fisher Scientific.
[0087] The endopeptidase may be trypsin. Trypsin (EC 3.4.21.4) is a serine protease (serine endopeptidase) present in the digestive tract of many vertebrates, where it hydrolyzes proteins. Trypsin cleaves peptide chains primarily at the carboxyl side of lysine or arginine residues. The optimum pH for the enzymatic activity of trypsin is about 8.0. Trypsin may be α-trypsin or β-trypsin. Preferential cleavage: Arg- / -Xaa or Lys- / -Xaa. The optimal activity temperature may vary depending on the type of trypsin. Trypsin may be isolated trypsin or synthetic trypsin. Trypsin may be bovine trypsin or porcine trypsin. Bovine trypsin may be isolated from bovine pancreas. Bovine trypsin may be recombinant bovine trypsin. Porcine trypsin may be isolated from porcine pancreas. Porcine trypsin may be recombinant porcine trypsin. Trypsin preparations may contain some contaminating chymotrypsin, which can be treated with TPCK (L-1-toluenesulfonamide-2-phenylethylchloromethylketone) to inhibit chymotrypsin activity. Free trypsin can be purchased from, for example, Sigma-Aldrich (Saint Louis, MO; Millipore Sigma, Burlington, MA, a subsidiary of Merck KGaA) or Promega (Madison, Wisconsin).
[0088] The endopeptidase can be chymotrypsin. Chymotrypsin (EC 3.4.21.1) is a serine protease that selectively cleaves peptide bonds on the carboxyl terminal side of large hydrophobic amino acids such as tryptophan, tyrosine, phenylalanine and methionine. Chymotrypsin can be commercially available from, for example, Promega Corp., Madison, WI (chymotrypsin, bovine pancreas).
[0089] The endopeptidase can be a LysC protease, also known as Lys-C. LysC is a serine protease that specifically hydrolyzes proteins at the carboxyl side of lysine residues. LysC can be commercially available from, for example, Promega Corp., Madison, WI. LysC can be a natural isolated enzyme or a recombinant LysC.
[0090] The endopeptidase may be a LysN protease, also known as Lys-N. LysN protease is a zinc metalloprotease that may be derived from, for example, Grifola frondosa. LysN cleaves proteins at the amino terminal side of lysine residues. LysN protease may be commercially available from, for example, Thermo Fisher Scientific, Inc.
[0091] The endopeptidase may be AspN protease, also referred to as Asp-N. AspN protease is a zinc metalloprotease derived from Pseudomonas fragi that can cleave proteins at the amino side of aspartic acid and cysteine residues produced by oxidation of cysteine residues. AsN protease can be commercially available from, for example, Thermo Fisher Scientific, Inc.
[0092] The endopeptidase may be GluC protease, also known as Glu-C. GluC specifically hydrolyzes proteins at the carboxyl side of glutamic acid residues. GluC is a serine protease isolated from Staphylococcus aureus. GluC can be commercially available from, for example, Thermo Fisher Scientific, Inc.
[0093] The endopeptidase can be ArgC protease, also known as Arg-C. ArgC is an endopeptidase that can cleave at the C-terminus or at arginine residues and lysine residues. ArgC can be isolated from Clostridium histolyticum. ArgC can be commercially available from, for example, Promega Corp., Madison, WI.
[0094] The method comprises enzymatic digestion of a pre-treated protein analyte to provide a plurality of peptides.The protein analyte can be, for example, a monoclonal antibody, an isolated immunoglobulin, a recombinant protein, an isolated protein, or a combination of different proteins.
[0095] In some examples, the enzyme: protein analyte ratio can be in the range of about 1:5 to about 1:150, about 1:10 to about 1:100, about 1:12 to about 1:50, or about 1:12 to about 1:40, about 1:20 to about 1:30, or about 1:25. The digestion can include incubating the denatured protein analyte with the immobilized enzyme or the free enzyme for a period of time at a temperature of about 32° C. to 40° C., about 36° C. to about 38° C., or about 37° C. The period of time can be in the range of about 5 minutes to about 75 minutes, about 10 minutes to about 60 minutes, or about 20 minutes to about 45 minutes, or about 30 minutes.
[0096] Immobilized trypsin may also be used. Trypsin immobilized on magnetic particles may be purchased commercially or may be prepared by any suitable technique known in the art. Trypsin may be immobilized on magnetic particles, such as magnetic beads.
[0097] In a specific example, magnetic beads or magnetic particles suitable for electromagnetic mixing can have an ultra-high magnetic response, for example, having a Bmax in the range of about 50-250emu / g, 80-120emu / g, or about 89emu / g. This is superior to many commercially available magnetic beads that have <40emu / g. The magnetic beads can have a Bmax of >10emu / g. 2 / g of high surface area. The magnetic beads can have a diameter of from about 10nm to about 200nm, about 50nm to about 150nm or about 100nm. The magnetic particles or beads can be surface functionalized by carboxyl, amino, hydroxyl, silica, streptavidin or endopeptidase moieties. Magnetite particles or beads can have a magnetite core. Magnetite particles or beads can have a magnetite core coated with a silica shielding layer. The silica shielding layer can be attached to a silane linker. The silane linker can be attached to a polymer. The polymer can be surface functionalized by carboxyl, amino, hydroxyl, silica, streptavidin, endopeptidase surface functional groups. In a specific embodiment, the magnetic beads or magnetic particles have a carboxyl surface functional group. In another specific embodiment, the magnetic beads or magnetic particles have a trypsin surface functional group.
[0098] Buffer
[0099] Any suitable buffer can be used for sample dilution and / or endopeptidase digestion, such as trypsin digestion. The buffer can have a pH in the range of about pH 7 to about pH 9. For example, the buffer can be an ammonium bicarbonate buffer, triethylammonium bicarbonate (TEAB) buffer, ammonium acetate buffer or TRIS-HCl buffer. For example, 0.1M ammonium bicarbonate, 50mM ammonium bicarbonate (pH 7.8) or 50mM Tris-HCl (pH 8) can be used. In some embodiments, the buffer does not include urea.
[0100] system
[0101] Magnetic beads have been widely used for sample preparation. However, the magnetic properties of the particles are usually only exploited during buffer exchange (supernatant removal). Mixing of the sample with the surface-functionalized beads is still usually achieved by mechanical agitation (e.g., shaking, pipette mixing). Using these types of traditional methods, magnetic particles may aggregate and cluster in discrete areas close to the container wall, greatly reducing the mixing efficiency.
[0102] The present disclosure provides an improved protein digestion method, comprising mixing a protein analyte with magnetic particles in a changing magnetic field. The changing magnetic field can utilize an oscillating electromagnetic field to completely disperse the magnetic beads, allowing optimal exposure and enhancing mixing with the surrounding liquid medium. Therefore, the reaction kinetics can be significantly improved.
[0103] The method uses an electromagnetic mixer to prepare samples efficiently and automatically. Suitable electromagnetic mixer components for processing fluids are described in WO2017093896, US2018-0369831, US2020-0011773 and WO2020016854 (Arnold et al.) and US10656147 (Campbell et al.), each of which is incorporated herein by reference in its entirety.
[0104] In many aspects, the fluid handling system can include a magnetic assembly, which includes multiple magnetic structures configured to generate a magnetic field gradient in a fluid container. The magnetic structure can be formed as multiple electromagnets configured to be actuated individually by a controller. Each electromagnet can generate a magnetic field in the fluid container. The electromagnet can be differentially actuated to generate a magnetic field gradient in the fluid container, thereby stirring, mixing or otherwise affecting the magnetic particles arranged in the fluid container. The activation of the electromagnet of the electromagnetic structure can generate a magnetic field gradient that affects the magnetic particles in the xy direction. In addition, the activation of the electromagnets of the multiple electromagnetic structures can generate a magnetic field gradient that affects the magnetic particles in the xy direction and the z direction.
[0105] The system may include a porous electromagnetic mixer actuated by a star-shaped electromagnet array so that each sample well (e.g., a commercial 24-well plate or 96-well plate) can be placed in a hole formed by four electromagnets. Each electromagnet is used for field control of, for example, four sample wells. By applying AC with different phase delays to the various electromagnets in the array, all wells can be activated simultaneously, producing a uniform suspension of magnetic particles in each well, minimizing the diffusion distance, and improving reaction kinetics. In any buffer exchange process, a steady-state magnetic field (DC) can be used to capture beads in the corners of the sample wells. The system may also include a temperature control module, which includes a hot plate, a plurality of temperature sensors, and a cooling fan placed above the sample plate.
[0106] The special design of the magnetic lens allows the electromagnetic mixer to be compatible with most commercial multi-well plates, such as 24-well plates or 96-well plates. The sample temperature can be precisely controlled by the structure of the hot plate, cooling fan and temperature sensor. It takes less than 5 minutes to heat the system from room temperature to 37°C (and another 5 minutes to 70°C if necessary), and the sample temperature can be maintained within ±1°C. Trypsin digestion of Herceptin was evaluated to test the electromagnetic mixer. A mixture of Herceptin (trastuzumab; 10 mg / mL) and trypsin (1 mg / mL) was incubated using vortex mixing (37°C) or electromagnetic mixing in the current device (37°C).
[0107] Effective mixing of large sample volumes (>1 mL) is challenging for mechanical stirring, as classical 2-D shaking cannot bring particles to the top portion of the solution, and extensive vertical shaking can cause problems with solution splashing and droplet attachment to the vial cap / lid. Effective and uniform 3-D bead mixing of large sample volumes can be achieved with a two-layer electromagnet structure.
[0108] For broad assay coverage, the system is designed to be compatible with both high magnetic response particles (e.g., ferrimagnetic beads) and low response particles (e.g., superparamagnetic beads) by adjusting the AC waveform applied to the electromagnet set. Even for samples containing low response superparamagnetic beads, the power consumption is less than 5W.
[0109] The AC frequency of the electromagnetic field can be 300 Hz and the field strength can be designed to be 31 mT pp (adjustable through the user interface). Different signal phases can be controlled for each electromagnet to achieve optimal suspension of magnetic particles. The system can be expanded from a single well controlled by 4 electromagnets to 96 wells controlled by 117 electromagnets, each shared by 4 wells.
[0110] Various forms of electromagnetic mixers can be used for rapid and automated sample preparation. The use of an AC driven oscillating magnetic field can allow for a uniform "dynamic mist" of magnetic bead suspensions, allowing for optimal exposure and enhanced mixing with the surrounding liquid medium. Reaction kinetics can be significantly improved using these systems. The design of the "star-shaped" magnetic lens makes the system compatible with commercial 96-well plates and magnetic particles. The two-layer electromagnet structure can be used for efficient 3-D mixing of large volume samples up to 2 mL. The system can include an integrated temperature control module. The system can be used for ultra-fast sample preparation devices for high-throughput analysis.
[0111] For samples with larger volumes (e.g., >0.5 mL), a two-layer electromagnet structure can be used to incorporate active mixing in the z direction in addition to xy mixing. Using this configuration, 3-D uniform particle distributions of samples up to 2 mL can be successfully observed.
[0112] Significantly improved reaction kinetics were observed using a system that included a magnetic mixer. Using the BSA digestion model, a 5-minute digestion time was sufficient to achieve higher yields than a 2-hour digestion using a thermo-shaker. In addition, by adding magnetic particles to the reaction system, no significant surface adsorption was observed.
[0113] method
[0114] In traditional solution digestion, protein analytes are denatured by strong chaotropic agents such as urea or thiourea. This step is followed or combined with disulfide reduction using a reducing agent such as tris(2-carboxyethyl)phosphine (TCEP) or dithiothreitol (DTT). The free sulfhydryl groups on cysteine residues are then alkylated with an alkylating agent such as iodoacetamide or iodoacetic acid to irreversibly prevent the free sulfhydryl groups from reforming disulfide bonds. The denatured, reduced, and alkylated proteins are then digested by endopeptidases (e.g., trypsin, chymotrypsin, Glu-C, and Lys-C), which hydrolytically cleave peptide bonds and fragment the proteins into peptides. The last two steps of the classical method can be very time consuming and may require 6 to 20 hours or more to complete sample preparation.
[0115] A method for characterizing a protein analyte is provided, comprising pre-treating and enzymatically digesting the protein analyte to provide a plurality of peptides. The plurality of peptides can be analyzed by a method comprising mass spectrometry (MS). The plurality of peptides can be separated and analyzed by, for example, liquid chromatography and mass spectrometry (LC-MS or LC-MS / MS). The pre-treatment can include mixing the protein analyte and a chaotropic agent in an aqueous solution with magnetic particles in a changing magnetic field (to provide a denatured protein solution); adding a reducing agent (to reduce cysteine disulfide bonds) to provide a reduced, denatured protein analyte; and exposing the denatured protein analyte to an alkylating agent (to alkylate cysteine thiol-SH groups) to provide an alkylated protein analyte. The method can include quenching excess alkylating agent by adding a reducing agent to the alkylated protein analyte. Digestion can include mixing the alkylated protein analyte with an endopeptidase to provide a plurality of peptides.
[0116] The various peptides can be separated using chromatographic techniques. The peptides can be analyzed using techniques including mass spectrometry. The peptides can be separated and analyzed using LC-MS or LC-MS / MS. Protein analytes; reduced, denatured protein analytes; alkylated protein analytes; and / or peptides can be separated and characterized using LC-MS or LC-MS / MS, for example, before, during, or after the method, respectively.
[0117] The protein analyte can be pretreated, including electromagnetic mixing with eMB in a varying magnetic field, so as to effectively denature, reduce and alkylate the protein analyte. Denatured, reduced and alkylated protein analytes can be mixed with free trypsin in a preselected ratio, for example, a protein analyte:trypsin 25:1 (w / w) ratio, or with trypsin immobilized on an eMag Bead according to the present disclosure. The magnetic mixer digestion temperature of Ty-eMB is set to 37°C. After incubation, 2% (v / v) formic acid can be added to the solution, and the sample can be analyzed by LC-MS / MS.
[0118] The protein digestion method of the present invention exhibits SQ%>95%, artifacts<5%, and PIM<10%. The protein digestion method of the present invention exhibits reproducibility, CV%<15%. Therefore, the method is at least comparable to the "in solution" method of the prior art.
[0119] In some embodiments, protein pretreatment including denaturation, reduction, alkylation and quenching can be completed in <45 minutes. The protein digestion process can be completed in <60 minutes, <45 minutes or <30 minutes. A specific advantage of the method of the present invention is that no vials or tubes need to be moved during the entire pretreatment and digestion process. For distribution purposes, the bead suspension is stable for at least 3 minutes. Therefore, the method of the present invention is simpler than the "in solution" method of the prior art and requires a shorter time to complete.
[0120] Set
[0121] The present disclosure provides a kit suitable for implementing the method provided herein. For example, a kit for preparing a protein analyte for characterization is provided, the kit comprising: a first container comprising a first magnetic bead; a chaotropic agent; a reducing agent; an alkylating agent; and an endopeptidase. The endopeptidase can be a free endopeptidase or an immobilized endopeptidase. According to the present disclosure, the immobilized endopeptidase can be immobilized on a second magnetic bead. The first magnetic bead can have a high magnetic response in the range of about 50-250emu / g, 80-120emu / g or about 89emu / g. The first magnetic bead can have a surface functional group selected from a carboxyl, amino, hydroxyl or silica group. The first magnetic bead does not contain an immobilized enzyme. The system of the present disclosure can include an electromagnetic mixer and a kit according to the present disclosure, the electromagnetic mixer including a plurality of electromagnets capable of generating an AC-driven oscillating magnetic field. Example
[0122] Example 1. Comparison of Prior Art "In Solution" Digestion Using Promega Trypsin (Amgen Method)
[0123] This example illustrates the prior art comparative "in solution" trypsin digestion of a protein analyte monoclonal antibody. The workflow of the prior art in solution trypsin digestion is as follows: Figure 2 (Figure above). Herceptin (trastuzumab) is a humanized IgG1κ monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 protein HER2. Trastuzumab can be produced in mammalian cell (Chinese hamster ovary) culture by recombinant DNA technology.
[0124] 0.1 mL of 10 mg / mL Herceptin (trastuzumab) stock solution was diluted to 1 mg / mL in 7.5 M guanidine hydrochloride (Gdn·HCl, Sigma) and 0.25 M Tris buffer (pH 7.5). 6 μL of 0.5 M dithiothreitol (DTT, ThermoFisher) was added to the mixture and then vortexed at 1000 RPM for 30 minutes at room temperature. 14 μL of freshly prepared 0.5 M 2-iodoacetamide (IAM, Thermo Fisher) was added to the mixture and incubated in the dark at room temperature for 15 minutes. 8 μL of 0.5 M DTT was added to the mixture to destroy excess IAM by vortexing for 30 minutes. In the desalting step, the buffer was replaced with 0.1 M ammonium bicarbonate (Fluka) using a Vivaspin500 centrifugal concentrator (MWCO 10 kDa, Sigma) and a Spectrafuge 16M microcentrifuge. Lyophilized trypsin (Promega, sequencing grade or gold grade porcine trypsin) was dissolved in suspension buffer to a final concentration of 1 mg / mL. Trypsin was added to the prepared monoclonal antibody solution at a ratio of 1:25 and vortexed and incubated at 37°C for 30 minutes. The final digest was quenched by adding 0.2% formic acid (FA, Sigma) to the solution. The digested samples were analyzed using LC-MS / MS.
[0125] Example 2. Magnetic bead digestion using bovine trypsin-coated eMag Beads or free bovine trypsin
[0126] This example illustrates the eMag digestion process of the present invention for monoclonal antibodies, first using only non-enzymatic magnetic beads as micro-stirring bars for efficient denaturation, reduction, alkylation and quenching, followed by digestion using either bovine trypsin-coated eMagBeads or free bovine trypsin (Sigma T8802, TPCK-treated trypsin from bovine pancreas).
[0127] Place 10 μL of 5% magnetic beads (carboxylated beads, used only as a micro stir bar for mixing) into the tube and remove the water. The B-500-1-BW uses Lodestone's eMagBead, functionalized with carboxyl groups, and used only as a micro stir bar for mixing during the denaturation / reduction / alkylation / quenching steps. Add 10 μL of 10 mg / mL Herceptin stock solution to the tube and then mix with 10 μL of trifluoroethanol (TFE, Sigma). Add 2 μL of 0.25M DTT to the mixture and mix on an electric mixer at approximately 45°C for 45 minutes. Add 2 μL of 0.5M IAM to the mixture and mix on an electric mixer at room temperature in the dark for 30 minutes. Add 2 μL of 0.25M DTT to quench excess IAM and incubate at room temperature for 45 minutes. 120 μL of water, 7.5 mg of Ty-eMB-06 (eMagBead coated with bovine trypsin) and 60 μL of 0.1 M ammonium bicarbonate were added to dilute the solution. The solution was then digested for 30 minutes at 37°C on an electric mixer. Alternatively, when the magnetic beads were used only as a stirring bar, trypsin-coated magnetic beads were not added, but free trypsin was added at a ratio of 1:25 enzyme / mAb at this step. After digestion, the magnetic beads were removed and 4 μL of 10% FA was added to the solution to quench the digestion. The digested samples were analyzed using LC-MS / MS.
[0128] Example 3. Magnetic bead digestion using eMag Beads coated with recombinant porcine trypsin
[0129] This example illustrates the inventive eMag digestion process of a monoclonal antibody, first using only non-enzymatic magnetic beads as micro-stirring bars for efficient denaturation, reduction, alkylation and quenching, followed by digestion using recombinant porcine trypsin-coated eMagBeads.
[0130] 10 μL of 5% magnetic beads (carboxylated beads, used only as a micro stir bar for mixing) were placed in a tube and the water was removed. 10 μL of 10 mg / mL Herceptin stock solution was added to the tube and then mixed with 10 μL of trifluoroethanol. 2 μL of 0.25M DTT was added to the mixture and mixed on an electric mixer at about 45°C for 45 minutes. 2 μL of 0.5M IAM was added to the mixture and mixed on an electric mixer at room temperature in the dark for 30 minutes. 2 μL of 0.25M DTT was added to quench excess IAM and incubated at room temperature for 45 minutes. The solution was diluted by adding 120 μL of water and 7.5 mg of Ty-eMB-10 (eMagBead coated with recombinant porcine trypsin) and 60 μL of 0.1M ammonium bicarbonate. Then digested on an electric mixer at 37°C for 30 minutes. After digestion, the magnetic beads were removed and 4 μL of 10% FA was added to the solution to quench the digestion. It was found that the time for sample preparation could be reduced. The digested samples were analyzed using LC-MS / MS.
[0131] Example 4. LC-MS / MS conditions
[0132] An Agilent 1290HPLC system with a Phenomenex Kinetex 2.6μm Polar C18 100A, 150x2.1 mm column was used at 50°C, using a gradient of eluent A as water + 0.1% formic acid and eluent B as acetonitrile + 0.1% formic acid. The injection volume was set to 5μL. The characteristic peptides and monoclonal antibodies were analyzed using a SCIEX X500B.
[0133] Example 5. UV Analysis and LC-MS / MS Peptide Mapping of Herceptin
[0134] The pretreatment and enzyme digestion methods of the present invention according to Examples 2 and 3 and the comparative prior art "in solution" method of Example 1 were each performed using the protein analyte Herceptin (trastuzumab). The methods of the present invention each include pretreating the protein analyte in a changing magnetic field in the presence of first magnetic beads to provide a pretreated protein analyte; and enzymatically digesting the pretreated protein analyte to provide a plurality of peptides.
[0135] Briefly, the methods of the present invention according to Examples 2 and 3 each used the chaotropic agent TFE, the reducing agent DTT, the alkylating agent IAM, quenched with added DTT, and enzymatic digestion was performed in ammonium bicarbonate buffer using either immobilized trypsin (eMagbeads coated with bovine trypsin) or free trypsin (Promega trypsin), and the final digest was quenched with formic acid.
[0136] In short, Figure 2The comparative prior art "in solution" method of Example 1 shown in the figure above uses the chaotropic salt guanidine hydrochloride, the reducing agent DTT and mixes by vortexing, alkylates with IAM, buffer exchanges into ammonium bicarbonate and free lyophilized trypsin (Promega, sequencing grade or gold grade porcine trypsin) using a Vivaspin 500 centrifugal concentrator, and quenches the final digest with formic acid.
[0137] Digested samples from the present invention and comparative prior art "in solution" methods were analyzed using LC-MS / MS. Figure 3 Peptide maps and ultraviolet (UV) spectroscopy and high-resolution mass spectrometry (MS) results of the monoclonal antibody Herceptin treated with three different methods are shown: (i) trypsin "in solution" of the prior art, (ii) eMag-immobilized trypsin of the present invention, and (iii) eMag-free trypsin of the present invention.
[0138] The prior art "in solution" trypsin method showed a higher number of unique peptides (138 unique peptides) than the eMag-immobilized trypsin method of the present invention (119 unique peptides) or the eMag-free trypsin method (107 unique peptides), as shown in FIG. Figure 3 , as shown in Table 1.
[0139] In general, the eMag process pathways of the present invention, the eMag immobilized trypsin process and the eMag free trypsin process, exhibited fewer process-induced modifications than the comparative prior art "in solution" free trypsin process, as shown in Table 1.
[0140] Compared to the eMag-immobilized trypsin method of the present invention (58 missed cleavages) or the eMag-free trypsin method (46 missed cleavages), the prior art "in solution" free trypsin method showed a higher number of undesired missed cleavages, such as Figure 3 , as shown in Table 1.
[0141] In contrast, the prior art "in solution" trypsin digestion method exhibited a relatively high 1.6% area percentage of the undesired deamidated peptide VVSVLTVLHQDWLNGK (SEQ ID NO: 1), while the eMag-immobilized trypsin method of the present invention and the eMag-free trypsin method of the present invention did not exhibit a measurable area % of the deamidated peptide, such as Figure 3 , as shown in Table 1.
[0142] In contrast, the prior art "in solution" trypsin method exhibited a relatively high area percentage of 2.8% of the undesirable deamidated peptide GFYPSDIAVEWESNGQPENNYK (SEQ ID NO: 2). In contrast, the eMag-immobilized trypsin method of the present invention exhibited 1.0%, while the eMag-free trypsin method of the present invention exhibited no measurable area percentage of this deamidated peptide, as shown in FIG. Figure 3 , as shown in Table 1.
[0143] Although the "in solution" free trypsin method showed lower DTLMISR (SEQ ID NO: 4) methionine oxidation (2.6%) compared to the prior art, it was found that for the two eMag pathways of the present invention, the 6-10% oxidation of DTLMISR (SEQ ID NO: 4) could be reduced to <5% after T adjustment (temperature adjustment) pretreatment.
[0144] The reproducibility of the eMag tryptic digest of the present invention and the tryptic digest in prior art solution of Herceptin was evaluated by LC-MS / MS analysis.
[0145] In general, the eMag digestion methods of the present invention using eMag-immobilized trypsin and eMag-free trypsin exhibited fewer unique peptides, fewer missed cleavages, and lower deamidation area % of the VVSVLTVLHQDWLNGK (SEQ ID NO: 1) peptide and the GFYPSDIAVEWESNGQPENNYK (SEQ ID NO: 2) peptide when compared to the prior art "in solution" free trypsin methods.
[0146] Both the eMag-immobilized trypsin and eMag free trypsin workflows of the present invention were able to demonstrate inhibition SQ%>95%, artifacts <5%, deamidation <5%, and digestion time <60 minutes. Each of the prior art "in solution", eMag immobilized, and eMag free trypsin methods demonstrated 0% deamidation of VSNK (SEQ ID NO:3). * For both eMag pathways of the present invention, 6%-10% oxidation of DTLMISR (SEQ ID NO:4) can be reduced to <5% after T-adjust (temperature adjustment) pretreatment.
Claims
1. A method for preparing a protein analyte for characterization, the method comprising pre-treating the protein analyte in the presence of first magnetic beads in a varying magnetic field to provide a pre-treated protein analyte; and The pre-treated protein analyte is enzymatically digested to provide a plurality of peptides.
2. The method of claim 1, wherein the characterization comprises The various peptides were analyzed, including by LC-MS / MS.
3. The method of claim 1, wherein the pretreatment comprises The protein analyte and the chaotropic agent in an aqueous buffer are mixed with the first magnetic beads in the changing magnetic field to provide a denatured protein solution.
4. The method of claim 3, wherein the mixing comprises A reducing agent is added to the denatured protein solution to provide a reduced denatured protein analyte.
5. The method of claim 4, wherein the mixing comprises The denatured protein analyte is exposed to an alkylating agent to provide an alkylated protein analyte.
6. The method of claim 5, wherein the mixing comprises Excess alkylating agent is quenched by adding a reducing agent to the alkylated protein analyte to provide the pretreated protein analyte.
7. The method of any one of claims 1 to 6, wherein the digestion comprises The pretreated protein analyte is mixed with an endopeptidase in the presence of the first magnetic beads in a varying magnetic field to provide the plurality of peptides.
8. The method of any one of claims 1 to 7, wherein the endopeptidase is selected from the group consisting of trypsin, chymotrypsin, LysC, LysN, AspN, GluC and ArgC.
9. The method of claim 8, wherein the endopeptidase is a free endopeptidase or an immobilized endopeptidase.
10. The method of claim 9, wherein the immobilized endopeptidase is immobilized on the surface of a second magnetic bead.
11. The method of any one of claims 1 to 10, wherein the first magnetic beads and / or the second magnetic beads independently comprise ferrimagnetic particles, superparamagnetic particles, ferromagnetic particles, paramagnetic particles, or a mixture thereof.
12. The method of any one of claims 1 to 11, wherein the first magnetic bead and / or the second magnetic bead independently have a high magnetic response having a Bmax in the range of about 20emu / g to about 250emu / g, 40emu / g to 200emu / g, 50emu / g to 150emu / g, or 80emu / g to 100emu / g.
13. The method of any one of claims 1 to 12, wherein the first magnetic bead and / or the second magnetic bead independently have a diameter of> 5 m 2 / g high surface area.
14. The method of claim 11, wherein the first magnetic bead and / or the second magnetic bead independently further comprises a coating, optionally wherein the coating is selected from the group consisting of a silica shield, a silane linker, and a polymer coating.
15. The method of any one of claims 1 to 14, wherein the first magnetic bead and / or the second magnetic bead independently comprises a surface coated with functional groups, optionally wherein the surface coated with functional groups is selected from the group consisting of carboxyl, amino, hydroxyl, thiol, tosyl, epoxy, alkyl, vinyl and aromatic groups.
16. The method of any one of claims 1 to 15, wherein the first magnetic bead and / or the second magnetic bead independently comprises a bioaffinity adsorbent, optionally selected from the group consisting of streptavidin, avidin, neutravidin, captavidin and biotin.
17. The method of any one of claims 1 to 16, wherein the first magnetic beads do not comprise an immobilized endopeptidase.
18. The method of any one of claims 1 to 17, wherein the varying magnetic field is generated in an electromagnetic mixer.
19. The method of claim 18, wherein the electromagnetic mixer comprises a plurality of electromagnets capable of generating an AC driven oscillating magnetic field.
20. The method of any one of claims 1 to 19, wherein the protein analyte is selected from the group consisting of a monoclonal antibody, an isolated immunoglobulin, a recombinant protein, an isolated protein, and a complex protein sample; optionally, wherein the complex protein sample is selected from the group consisting of a tissue sample, a blood sample, a serum sample, and a plasma sample.
21. The method of any one of claims 3 to 20, wherein the chaotrope is an organic chaotrope.
22. The method of claim 20, wherein the organic chaotropic agent is selected from the group consisting of trifluoroethanol (TFE), ethanol, 2-propanol, n-butanol, and phenol.
23. The method of any one of claims 1 to 22, wherein the chaotropic agent is an immobilized chaotropic agent; optionally, wherein the chaotropic agent is immobilized on the first magnetic bead or on a third magnetic bead.
24. The method of any one of claims 4 to 23, wherein the reducing agent is selected from the group consisting of dithiothreitol (DTT), dithioerythritol (DTE), tris(2-carboxyethyl)phosphine hydrochloride (TCEP), β-mercaptoethanol (βME) and L-glutathione (GSH).
25. The method of any one of claims 5 to 24, wherein the alkylating agent is selected from the group consisting of 2-iodoacetamide (IAM), iodoacetic acid (IAC), and chloroacetamide (CAA).
26. The method of any one of claims 1 to 25, wherein the pretreatment is completed within a time period ranging from 5 minutes to 90 minutes.
27. The method of any one of claims 1 to 26, wherein the enzymatic digestion is completed within a time period of 5 minutes to 60 minutes.
28. The method of any one of claims 1 to 27, wherein the pretreatment and the enzymatic digestion are performed sequentially or simultaneously.
29. A kit for preparing a protein analyte for characterization according to any one of claims 1 to 28, the kit comprising a first container comprising first magnetic beads; Chaotropic agents; reducing agent; an alkylating agent; and Endopeptidase.
30. The kit of claim 29, wherein the first magnetic bead comprises a surface coated with functional groups, optionally wherein the surface coated with functional groups is selected from the group consisting of carboxyl, amino, hydroxyl, thiol, tosyl, epoxy, alkyl, vinyl and aromatic groups; optionally wherein the first magnetic bead does not comprise an immobilized endopeptidase.
31. The kit of claim 29 or 30, wherein the endopeptidase is selected from the group consisting of trypsin, chymotrypsin, LysC, LysN, AspN, GluC and ArgC.
32. The kit of any one of claims 29 to 31, wherein the endopeptidase is a free endopeptidase or an immobilized endopeptidase.
33. The kit of claim 32, wherein the immobilized endopeptidase is immobilized on second magnetic beads.
34. The kit of any one of claims 29 to 33, wherein the chaotrope is a free chaotrope or an immobilized chaotrope.
35. The kit of claim 34, wherein the immobilized chaotropic agent is immobilized on the first magnetic bead or on the third magnetic bead.
36. A system comprising a kit according to any one of claims 29 to 35 and an electromagnetic mixer comprising a plurality of electromagnets capable of generating an AC driven oscillating magnetic field.
